---
document_datetime: 2025-01-24 16:23:45
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tadalafil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tadalafil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.3838787
conversion_datetime: 2025-12-28 18:51:30.405372
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tadalafil Mylan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0028               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                 | 22/01/2025                          |                                             | PL                               |           |
| IB/0026              | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement | 13/03/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------|
| IA/0027   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 07/03/2024 | n/a |            |
| IB/0025/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 12/12/2023 | n/a | B.II.b.5.z |

<div style=\"page-break-after: always\"></div>

|           | during the manufacture of the finished - Other variation                                                                                                                                                                                                                                    |            |            |                        | applied product      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------|
| IB/0024   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                              | 25/10/2023 | 04/10/2024 | SmPC and PL            |                      |
| WS/2431   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 12/05/2023 | n/a        |                        |                      |
| IA/0022   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                | 20/07/2022 | n/a        |                        |                      |
| N/0021    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                            | 15/06/2022 | 04/10/2024 | PL                     |                      |
| T/0020    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                         | 12/08/2021 | 15/09/2021 | SmPC, Labelling and PL |                      |
| IA/0019/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites change - Deletion of                                                                                                                                                       | 04/03/2021 | 15/09/2021 | Annex II and PL        | A.7 - Administrative |

<div style=\"page-break-after: always\"></div>

|             | manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                 |                                          |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------------|
| IAIN/0018/G | for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a (replacement or addition)                                                                                                    | 17/06/2020 | n/a        |                 | This was an application new manufacturer |
| IAIN/0017   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                       | 11/12/2019 | 17/09/2020 | Annex II and PL |                                          |
| IAIN/0016/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - control/testing | 18/09/2019 | 17/09/2020 | Annex II and PL | Not including batch                      |

<div style=\"page-break-after: always\"></div>

| R/0014      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                    | 29/05/2019   | 31/07/2019   | SmPC, Labelling and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Tadalafil Mylan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0015/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                          | 01/07/2019   | n/a          |                          |                                                                                                                                                                                                                                                                                 |
| N/0013      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                           | 07/03/2019   | 31/07/2019   | PL                       |                                                                                                                                                                                                                                                                                 |
| IA/0012/G   | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 14/01/2019   | n/a          |                          |                                                                                                                                                                                                                                                                                 |
| T/0011      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                        | 25/07/2018   | 03/08/2018   | SmPC, Labelling and      |                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            | PL                    |                       |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------|
| IB/0009     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 08/11/2017 | 12/04/2018 | SmPC                  |                       |
| IAIN/0010/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch place                                                                                                                                                                                                                                                                                                                                                                                                                  | 07/11/2017 | n/a        |                       | control/testing takes |
| IB/0008/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference | 27/06/2017 | 12/04/2018 | SmPC, Annex II and PL |                       |

<div style=\"page-break-after: always\"></div>

|           | product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                        |                                                                                        |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------|
| A31/0005  | Pursuant to Article 31 of Directive 2001/83/EC, several member states requested on 14 December 2016 the opinion of the European Medicines Agency further to critical findings following GCP inspections by the Austrian and Dutch inspection authorities at Micro Therapeutic Research Labs Ltd, India. The CHMP was requested to assess the impact thereof on the benefit-risk balance of several products (amongst them Tadalafil Mylan) and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended, revoked or the marketing | 23/03/2017 | 23/06/2017 |                        | Please refer to the assessment report: Tadalafil Mylan - EMEA/H/A31/1450/C/003787/0005 |
| IB/0007   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18/04/2017 | 12/04/2018 | SmPC, Labelling and PL |                                                                                        |
| IAIN/0006 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                              | 16/02/2017 | 23/06/2017 | SmPC, Labelling and PL |                                                                                        |
| IB/0004   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/10/2016 | 23/06/2017 | SmPC, Labelling and    |                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | assessment done under A 45/46 - Other variation                                                                                                                                                                                                              |            |            | PL          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IG/0647 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                              | 11/01/2016 | n/a        |             |
| IA/0002 | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                  | 21/12/2015 | n/a        |             |
| IB/0001 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 16/11/2015 | 02/12/2015 | SmPC and PL |